Gilde Healthcare, a specialized healthcare investor, and KLIFO A/S, a drug development consultancy, have announce that Gilde’s Private Equity fund has acquired a majority stake in KLIFO.
Gilde Healthcare aims to support KLIFO’s growth in the dynamically developing pharma outsourcing sector, the companies state in a press release.
Alejandra Mørk will continue as CEO of KLIFO
Headquartered in Copenhagen in Medicon Valley, KLIFO has also offices in Sweden, Germany and the Netherlands. The company offers multidisciplinary consulting and operational solutions allowing pharmacos, biotechs and medical device companies to successfully bring their product to market – from clinical research to approval, they state in the press release.
The acquisition by Gilde Healthcare will facilitate the next steps in KLIFO’s expansion, it states. This means deepening its service offering and geographic footprint, which will be achieved through organic investments and an active buy and build strategy. KLIFO’s management will continue unchanged, and Alejandra Mørk will continue as CEO of KLIFO and will remain a significant shareholder.
“In the past few years, KLIFO has delivered significant growth, and now is the right time for the company to take the next step on its journey. This strategic investment, along with the support of Gilde’s experienced healthcare professionals, will help sustain our growth ambitions and enable KLIFO to realise its full potential, creating solutions and value for our clients,” says Alejandra Mørk, CEO of KLIFO.
Founded in 1994
KLIFO was founded in Denmark as a Clinical Research Organisation (CRO) in 1994. In 2008, Alejandra Mørk acquired KLIFO and assumed the role of CEO. KLIFO has over the years expanded its geographical footprint by establishing an office in Sweden, acquiring the Munich-based Medicomp GmbH and the Dutch company MediServ. Today, KLIFO has offices in Denmark, Sweden, Germany and The Netherlands and employs more than 150 employees.